Yonjin Venture
Signal active
Investment Firm
Overview
Yonjin Venture is an investment firm specializing in investing in early and mid-stage life science companies.
It focuses on the innovative technologies in therapeutics, diagnostics, and medical devices. The firm is a sub-organization of Yongjin Group and the sister firm of Yonghua Capital.
The Cambridge, Massachusetts-based firm was established in 2018.
Highlights
Founded
2016
Industry
Venture Capital
Employees
11-50
Investment
18
Lead Investment
3
Exits
5
Stages
Early Stage Venture, Late Stage Venture
Investor Type
Venture Capital
Location
Cambridge, Massachusetts, United States, North America
Contact Information
Social
Profile Resume
Yonjin Venture, established in 2016 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture investments across Biotechnology, Health Care, Medical, Therapeutics, Oncology, Financial Services, Venture Capital, Pharmaceutical, Precision Medicine, Finance. The organization boasts a portfolio of 18 investments, with an average round size of $28.6M and 5 successful exits. Their recent investments include EvolveImmune Therapeutics, Elm Street Ventures, Pfizer, Takeda Ventures, HistoSonics. The highest investment round they participated in was $20.9B. Among their most notable exits are EvolveImmune Therapeutics and Elm Street Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Yonjin Venture has made 18 investments. Their most recent investment was on Nov 16, 2023, when EvolveImmune Therapeutics raised $37.4M.
Yonjin Venture has made 4 diversity investments. Their most recent diversity investment was on Dec 13, 2022, when HistoSonics raised $85.0M.
investments
18
Diversity investments
4
Lead investments
3
Number of exits
5
Investments
18
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Aug 16, 2022 | Bluejay Therapeutics | Biotechnology | 41.0M |
| Oct 25, 2022 | Intressa Vascular | Health Care | 12.0M |
| Dec 13, 2022 | HistoSonics | Health Care | 85.0M |
| Nov 16, 2023 | EvolveImmune Therapeutics | Biotechnology | 37.4M |
Exits
5
Funding Timeline
Funding rounds
18
Investors
0
Funds
0
Funding Rounds
18
Yonjin Venture has raised 18 rounds. Their latest funding was raised on Nov 16, 2023 from a Venture Round - EvolveImmune Therapeutics round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Aug 16, 2022 | Series B - Bluejay Therapeutics | - | 41.0M | - |
| Oct 25, 2022 | Funding Round - Intressa Vascular | - | 12.0M | - |
| Dec 13, 2022 | Convertible Note - HistoSonics | - | 85.0M | - |
| Nov 16, 2023 | Venture Round - EvolveImmune Therapeutics | - | 37.4M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
News
Sep 13, 2024
Crunchbase News - The Week’s 10 Biggest Funding Rounds: Another Big Week For Biotech And AI
Funding Round
Nov 16, 2023
EvolveImmune Therapeutics raised $37398371 on 2023-11-16 in Venture Round
Funding Round
Dec 13, 2022
HistoSonics raised $85000000 on 2022-12-13 in Convertible Note
Funding Round
Oct 25, 2022
Intressa Vascular raised $11954585 on 2022-10-25 in Funding Round
Funding Round
Aug 16, 2022
Bluejay Therapeutics raised $41000000 on 2022-08-16 in Series B
Funding Round
Aug 15, 2022
Regenacy Pharmaceuticals raised $9300000 on 2022-08-15 in Series B